Genentech continues oral SERD momentum in breast cancer: Clinical Report

Amid a week of clinical setbacks, a notable exception was Genentech’s oral SERD, which had its second Phase III win this year — this time showing superiority to standard of care in early breast cancer patients, a new setting for the class.

The Genentech unit of  Roche (SIX:ROG; OTCQB:RHHBY) announced Tuesday that giredestrant, a next-generation selective estrogen degrader and full antagonist, met the primary endpoint of improvement in invasive disease-free survival versus standard of care endocrine therapy in the Phase III lidERA study in ER+/HER2- early-stage breast cancer patients...